Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a global Contract Development and Manufacturing Organization (CDMO) that provides end-to-end development and manufacturing solutions for the pharmaceutical and biotech industries. Operating as a division of Piramal Pharma Limited, the company's mission is to enhance client value and reduce the burden of disease, with a strong emphasis on patient centricity. Its operational headquarters are located in Lexington, Kentucky, USA.

Piramal Pharma Solutions offers a comprehensive range of services across the entire drug lifecycle, including drug discovery, process and pharmaceutical development, clinical trial supplies, and commercial manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company specializes in advanced capabilities such as highly potent APIs (HPAPIs), antibody-drug conjugations (ADCs), sterile fill/finish services, peptide products, and biologics, including vaccines and gene therapies. PPS serves both innovator and generic pharmaceutical companies globally through an integrated network of facilities across North America, Europe, and Asia.

In recent news, Piramal Pharma Solutions announced a partnership with Botanix to support drug substance development and unveiled a new Payload-Linker Suite at its Riverview, Michigan facility in May 2026. The company also commemorated the 20th anniversary of its Morpeth facility in March 2026 with the procurement of a Korsch X3 Tablet Press. Piramal Pharma Limited, the parent company, reported a recovery in biopharma funding and healthy order inflows for its CDMO business in Q4 and full-year FY26. Herve Berdou serves as the Chief Operating Officer for Piramal Pharma Solutions.